Literature DB >> 2456980

An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern.

L J Medeiros1, S A Michie, D E Johnson, R A Warnke, L M Weiss.   

Abstract

We applied a panel of antibodies to formalin-fixed, paraffin-embedded sections of 55 renal cell carcinomas using a three-stage immunoperoxidase technique. The antibody panel included two anti-keratins, AE1 and CAM5.2, anti-epithelial membrane antigen (EMA), anti-vimentin, anti-S100 protein, and the anti-leukocyte marker PD7/26. Forty-eight of 55 renal cell carcinomas expressed keratins. CAM5.2 stained 46 tumors (84%) and AE1 stained 37 neoplasms (67%). AE1 reacted with two CAM5.2-negative tumors. EMA was expressed by 35 carcinomas (64%), including three of the CAM5.2-negative neoplasms. Therefore, using all three antibodies, 50 neoplasms (91%) expressed antigens of epithelial differentiation. Anti-EMA and AE1 were complementary to each other; the combination stained 46 of the carcinomas, comparable with CAM5.2 alone. Vimentin was expressed by 26 tumors (47%), and S100 was expressed by one. PD7/26 did not stain any of the cases. Vimentin expression correlated with nuclear grade; low nuclear grade neoplasms infrequently expressed vimentin, while the converse was true for high nuclear grade tumors. Keratin expression was related to tumor cell type and histologic pattern, as fewer neoplasms of clear cell type and with a solid pattern expressed keratins. In contrast, all papillary and eight of nine (89%) spindled carcinomas expressed keratins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456980     DOI: 10.1016/s0046-8177(88)80016-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Expression of the human nephron differentiation molecules in renal cell carcinomas.

Authors:  D Droz; D Zachar; L Charbit; J Gogusev; Y Chrétein; L Iris
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

2.  Immunopathology of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex.

Authors:  R J Cote; C Cordon-Cardo; V E Reuter; P P Rosen
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

3.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.

Authors:  W Domagala; J Lasota; J Bartkowiak; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

4.  Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.

Authors:  W Domagala; J Lasota; A Dukowicz; M Markiewski; G Striker; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

5.  Clear cell sarcoma of the kidney in an adult.

Authors:  M D Jeffers; D Lanigan; P J Paterson; C J Stewart
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

Review 6.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

7.  Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.

Authors:  A Handra-Luca; S-M Hong; K Walter; C Wolfgang; R Hruban; M Goggins
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

8.  N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma.

Authors:  Carl Ludwig Behnes; Bernhard Hemmerlein; Arne Strauss; Heinz-Joachim Radzun; Felix Bremmer
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

9.  Clear cell sarcoma of the kidney in a 62-year-old patient presenting with generalized pruritus.

Authors:  Yuxi Zhang; Jun Li; Yan Wang
Journal:  BMC Cancer       Date:  2019-11-01       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.